HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,501-7,512 of 27,277
Drug study icon
CompletedNCT00892125

Safety study of Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in schizophrenia

Official study title

Evaluation of the Effect of Carbamazepine on the Steady-state Pharmacokinetics of Paliperidone Extended Release in Clinically Stable Subjects With Schizophrenia or Bipolar I Disorder

This study has finished and is no longer accepting participants.

Location not clearly listed
Bipolarity, SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00838669

The Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

Official study title

Evaluation of the Effect of Food and Posture on the Pharmacokinetics of Paliperidone After a Single Administration of 12 mg ER OROS Paliperidone to Healthy Men

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00892320

Safety study of Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Schizophrenia

Official study title

A Randomized, Open-label, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Subjects

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 20–45
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT01116830

Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction for schizophrenia

Official study title

A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder

This study has finished and is no longer accepting participants.

In Orangeburg
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Hoffmann-La Roche
Drug study icon
CompletedNCT00077727

Galantamine added to antipsychotic treatment for cognitive concerns in schizophrenia

About this title

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Read the official source — NCT00077727
Official study title

A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT06259526

Effectiveness of Effectiveness and Safety of JS1-1-01 in depression

Official study title

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
DepressionMedication studyAges 18–65
Countries
China
Sponsor
Tasly Pharmaceutical Group Co., Ltd
Drug study icon
CompletedNCT00253136

Long-acting risperidone injection or placebo for schizophrenia symptoms

About this title

A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Read the official source — NCT00253136
Official study title

Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Janssen, LP
Drug study icon
CompletedNCT00246220

Three doses of extended-release methylphenidate for adults with ADHD

About this title

A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.

Read the official source — NCT00246220
What is this study about?

This study evaluated the safety and effectiveness of methylphenidate hydrochloride for people with ADHD.

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDMedication studyAges 18–65
Countries
Sponsor
Janssen Pharmaceutica N.V., Belgium
Drug study icon
CompletedNCT00253149

Risperidone, placebo, or haloperidol added to mood stabilizers for mania in bipolarity

About this title

A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder

Read the official source — NCT00253149
What is this study about?

This study evaluated the safety and effectiveness of risperidone for people with bipolarity.

This study has finished and is no longer accepting participants.

Location not clearly listed
BipolarityMedication studyAges 18–65
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00249132

Risperidone doses, haloperidol, or placebo for chronic schizophrenia

About this title

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

Read the official source — NCT00249132
Official study title

Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Janssen, LP
Drug study icon
CompletedNCT00249119

Risperidone doses compared with haloperidol for chronic schizophrenia

About this title

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

Read the official source — NCT00249119
Official study title

Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Janssen, LP
Drug study icon
CompletedNCT00253162

Risperidone for mania, then maintenance treatment in bipolarity

About this title

A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol

Read the official source — NCT00253162
What is this study about?

This study evaluated the safety and effectiveness of risperidone for people with bipolarity.

This study has finished and is no longer accepting participants.

Location not clearly listed
BipolarityMedication studyAges 18+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.